Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations

2019-07-04T21:32:51+00:00December 5th, 2015|Categories: Press Releases|Tags: , , , , , , , |

⟵  PRESS RELEASES PRESS RELEASE EAST HANOVER, [...]